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Dietary supplementation with L—arginine limits cell proliferation
in the remnant glomerulus
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Dietary supplementation with L-arginine attenuates glomerular injury
in renal-ablated rats. One effect of L-arginine is to increase nitric oxide
(NO) production by endothelial cells. NO directly reduces endothelin-1
production by endothelial cells and also inhibits platelet-derived growth
factor (PDGF) induced cell proliferation. Since subtotal renal ablation is
associated with an early phase of cell proliferation in the glomerulus that
precedes injury, we examined the effect of dietary supplementation with
L-arginine on glomerular cell proliferation and expression of the cytokine
endothelin-1 (ET-1). A first group of renal-ablated rats was untreated. A
second group of renal-ablated rats received L-arginine (1%) in the
drinking water. Two weeks after subtotal ablation renal cortical tissue was
snap frozen for immunohistochemical analysis for proliferating cell nu-
clear antigen (PCNA) expression and ET-1. Protein and total RNA was
extracted from sieved glomeruli. mRNA levels were quantitated by
co-amplification RT-PCR utilizing specific 5' and 3' primers for rat ET-1
and f3-actin. L-arginine reduced the number of PCNA positive nuclei in
remnant glomeruli, and Western blot Analysis of glomerular proteins also
showed that L-arginine reduced PCNA expression. Glomerular ET-1
mRNA levels and protein immunostaining declined in the rats receiving
L-arginine. We conclude that dietary supplementation with L-arginine
reduces early cell proliferation in the remnant glomerulus, an effect that
may be mediated, in part, by a decrease in ET-1 production.
and coworkers has shown that L-arginine increases urinary excre-
tion of the NO metabolites, nitrite and nitrate, in renal-ablated
rats [14]. NO can exert an antiproliferative effect on cells by two
mechanisms that may be important in the remnant glomerulus.
First, NO directly inhibits the synthesis of endothelin-1 (ET-1) by
endothelial cells [15], and, second, NO attenuates PDGF release
from endothelial cells [16].
The mechanism(s) responsible for the early phase of cell
proliferation in the remnant glomerulus have not been fully
elucidated, but endothelin-l (ET-1) and platelet-derived growth
factor (PDGF) have been implicated in this process [7, 17, 18]
because expression of both of these cytokines increases in glomer-
uli after subtotal renal ablation [19, 20]. Accordingly, we first
sought to determine if dietary supplementation with L-arginine
limited the early phase of cell proliferation in the glomeruli of
renal-ablated rats. We then sought to relate the effect of L-
arginine to changes in endothelin-1 in the remnant glomerulus.
Methods
Animal model
Ablation of 5/6 of renal mass leads to systemic hypertension,
proteinuria, and progressive glomerulosclerosis in the rat [1—3].
Glomeruli hypertrophy and intraglomerular pressure rises in
association with hyperfiltration [4, 5]. Later capillary collapse and
localized increases in mesangium develop, processes that contrib-
ute to the eventual destruction of the glomerular capillary tuft [6].
Studies have also shown that an early phase of mesangial cell
proliferation precedes glomeruloscierosis in the remnant glomer-
ulus [7, 8].
Klahr and coworkers have recently reported that dietary sup-
plementation with L-arginine lessens glomeruloscierosis in renal-
ablated rats [9]. L-arginine is a substrate for the nitric oxide
synthases (NOSs) [10], and NOS mRNA and enzyme activity can
be detected in cultured glomerular mesangial and endothelial
cells and in whole glomeruli [11, 12]. Dietary supplementation
with L-arginine has been shown to increase nitric oxide (NO)
production by endothelial cells [13], and recent studies by Ashab
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Experiments were performed with male Sprague-Dawley rats
weighing 217 8 g (Harlan Sprague-Dawley, Indianapolis, IN,
USA). After a 24-hour urine collection for determination of
urinary protein excretion rate, awake systolic blood pressure
(SBP) was measured by the tail cuff method, and 99mTCDTPA
was administered for determination of GFR. Following these
baseline determinations, rats were anaesthetized with a 1:1 mix-
ture of ketamine (100 mg/ml):xylazine (20 mg/mi), 0.15 ml per 100
g body wt intraperitoneally, and a 5/6 renal ablation was per-
formed by removal of the right kidney and ligation of two of the
three branches of the left renal artery.
After 5/6 renal ablation, the rats were randomly divided into
two groups. A first group received regular tap water (N = 18),
while a second group (N = 18) received tap water supplemented
with 1% anhydrous L-arginine (Sigma Chemical, St. Louis, MO,
USA). Both groups of renal ablated rats had free access to regular
lab chow containing 22.8% protein (Ralston Purina, St. Louis,
MO, USA).
Two weeks after renal ablation, measurements of SBP, GFR,
and urinary protein excretion were repeated. The rats were then
anaesthetized with Brietal (50 mg/kg), intraperitoneally, and the
kidneys were rapidly removed for analysis of mRNA, immunohis-
tochemistry, and protein expression.
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Measurement of urine protein excretion
Individual 24-hour urine samples were collected by placing
animals in metabolic cages (MED-TEC, Woodstock, Ontario,
Canada). All samples were collected under 1 ml of mineral oil.
Protein excretion was measured by sulfosalicylic acid precipita-
tion.
Measurement of glomerular filtration rate
GFR was determined by measuring 99mTCDTPA clearance, as
previously described [21]. A dose of 3.7 MBq of 99mTCDTPA
(London Regional Nuclear Pharmacy, London, Ontario, Canada)
was administered intraperitoneally using a 25 gauge needle with
setback attachment to prevent administration of isotope into
bowel or fat. Three blood samples of 200 d were taken from the
tail vein during light ether anaesthesia at 30, 60 and 90 minutes.
After centrifugation 50 jd aliquots of plasma were transferred into
counting tubes. 99"TC activity was counted for 60 seconds with a
sodium iodide crystal well counter (Searle Gamma Autowell 1185,
Nuclear Chicago, Chicago, IL, USA). Glomerular filtration rate
was calculated by a computer program using the slope intercept
method, incorporating background values, activity of a reference
standard, measurement times and decay corrections [21]. Results
were expressed as mi/mm/kg body wt. GFR was determined in six
normal rats prior to renal ablation, and in twelve rats from each of
the renal-ablated groups.
Glomerular isolation
Rats were anaesthetized with Brietal (50 mg/kg) intraperitone-
ally and the kidneys were rapidly removed. Perirenal fat was
strimmed off, the capsule was removed, and the cortex was
separated from the medulla. The cortical tissue was placed in
ice-cold PBS buffer (pH 7.4), cut into 2 mm3 pieces, and glomeruli
were isolated by the technique of differential sieving. For RNA
extraction, the cortical tissue from four separate kidneys was
pooled. For protein extraction, the cortical tissue from three
separate kidneys was pooled. The tissue was first passed through
a 250 im sieve and resuspended in ice-cold PBS before centrif-
ugation at 2000 rpm for 10 minutes at 4°C. The pellet was
resuspended in ice-cold PBS (pH 7.4) and drawn up through a 20
gauge needle and discharged three times, then centrifuged at 2000
rpm for 10 minutes at 4°C. The tissue pellet was resuspended in
ice-cold PBS (pH 7.4) and passed through a 106 m sieve and
then a 75 tm sieve. Glomeruli collected on the 75 m screen and
were finally resuspended in ice-cold PBS (pH 7.4). All solutions
were DEPC-treated. The purity of the final suspension was
determined by light microscopic examination. On average, there
were fewer than 5 to 10 tubular fragments per 100 glomeruli. This
suspension of giomeruli were then used for RNA isolation.
RNA isolation
Total RNA from both the glomerular and renal cortical tissue
was extracted by the single step method of Chomczynski and
Sacchi [221. Two milliliters of a solution containing 4 M guani-
dinium isothiocyanate and 0.1 M 2—mercaptoethanol was added to
the glomerular suspension and vortexed. 0.2 milliliters of 2 M Na
acetate, 2.0 milliliters of DEPC-treated phenol, and 0.4 milliliters
of chloroform were then added. The solution was placed on ice for
15 minutes and then centrifuged at 8000 rpm for 20 minutes. An
equal volume of isopropanol was added to the aqueous phase and
precipitated at —20°C for at 60 minutes. Total RNA was pelleted
by centrifugation at 8000 rpm for 20 minutes, resuspended in 300
jtl of a solution containing 4 M guanidinium isothiocyanate, 0.1 M
2-mercaptoethanol, 300 tl of isopropanol, and again precipitated
at —20°C for 60 minutes. After centrifugation, the RNA pellet was
resuspended in 300 d of cold 70% ethanol and stored in
DEPC-treated water at —70°C. The purity and concentration was
determined by measuring the optical densities at 260 and 280 nm
prior to use. The A260/A280 ranged from 1.75 to 1.95.
Co-amplification reverse transcriprion-polymerase chain
reaction (RT-PCR)
One microgram of total RNA (10 ,iil volume) was combined
with 10 U RNAsin and 300 pmol of random hexamers. The
mixture was heated to 65°C for five minutes and cooled on ice.
After addition of 100 U of Moloney Murine Leukemia Virus
reverse transcriptase (M-MLV-RT) 10 U of RNAsin, and 4 l of
5 x RT buffer so that the final volume was 20 d, the reaction
mixture was incubated at 42°C for two hours. The reaction was
stopped by heating at 95°C for five minutes. The RT products
were then diluted to 100 l with deionized water and stored at
—70°C prior to subsequent amplification.
Primers for the polymerase chain reaction (PCR) were de-
signed to flank at least one putative intron site. For endothelin-1,
the sense primer corresponded to base pairs 157 to 177 and the
antisense primer to base pairs 675 to 699 [23]. For /3-actin, the
sense primer corresponded to base pairs 331 to 354 and the
antisense primer to base pair 550 to 571 [24]. The two primers
were constructed to cross intron #2. The primer sequences were
as follows:
endothelin-1 5' CGT TGC TCC TGC TCC TTG ATG G
3' AAG ATC CCA GCC AGC ATG GAG ACG CG
rat /3-actin 5' AAC CCT AAG GCC AAC CGT GAA AAG
3' TCA TGA GGT AGT CTG TCA GGT
For amplification, 5 d of the RT product was combined with 6.5
tl of PCR mix containing 0.1 LM of each of the primer pairs and
2 units of Taq polymerase. Coamplification of /3-actin was per-
formed to standardize the amount of RNA subjected to reverse
transcription for each time point. The sample was placed onto a
Perkin Elmer DNA Thermal Cycler (Model 480) and heated to
94°C for four minutes, followed by 30 temperature cycles. Each
temperature cycle consisted of three periods: (1) denature, 94°C
for three minutes; (2) cool-anneal, 60°C for three minutes; (3)
heat-extend, 72°C for three minutes.
After amplification, the PCR products were separated by
electrophoresis on a 1.0% agarose gel containing ethidium bro-
mide, photographed, and transferred to a nylon membrane (Nit-
ran+, Scieicher and Schuell). The PCR product for /3-actin
increased when the number of cycles was increased from 26 to 34
cycles, so that the standard condition for PCR amplification was
set at 30 cycles.
The expected PCR product size for the primers was as follows:
endothelin-1, 260 base pairs; /3-actin, 240 base pairs. An antisense
oligonucleotide, synthesized to serve as amplification product-
specific probe for endotheiin-1, spanned base pairs 302 to 321
(5'CCC TI17G GTC TGT GGT CIT TG 3'). An antisense
oligonucleotide was synthesized to serve as amplification product-
specific probes for f3-actin and spanned base pairs 427 to 456
(5'CAC AAT GCC AGT GGT ACG ACC AGA GGC ATA 3').
Ingram et at: L-aiginine in the remnant glomenilus 1859
Fig. 1. Photomicrographs of proliferating cell nuclear antigen (PCNA)
immunoreactivity in glomeruli of renal-ablated rats (magnification — X500).
A. No imniunostaining in glomeruli when the primary antibody is omitted
from the protocol or replaced by non-immune rabbit serum. B. The typical
glomerular immunostaining for PCNA. PCNA positive nuclei were evi-
dent in the glomeruli from both groups of renal-ablated rats.
By design, each oligonucleotide localized to a sequence that was
inside the amplification primer sequences. The oligonucleotides
were labeled with 32P-ATP (4500 Ci/mmol) utilizing T4 DNA
kinase for 5' end labeling. Nylon filters were hybridized overnight
at 55°C, washed and exposed to X-ray film at room temperature
with an intensifying screen for 30 to 120 minutes.
The autoradiograms were quantitated with a GS 300 Transmit-
tance/Reflectance Scanning Densitometer (Hoefer Scientific In-
struments) utilizing a MacIntosh Classic II (System 7.0) and
Dynamax HPLC Method Manager (V1.2).
Western blot analysis of glomerular proteins
Glomeruli were isolated by differential sieving as described
above, and then homogenized in one milliliter of buffer containing
600 mvi NaCI and 15 mivi Tris-HC1. The homogenates were
centrifuged at 3000 rpm for 10 minutes. The supernatant was then
separated and the protein concentration of the lysate was deter-
mined [25]. For Western blot analysis, forty micrograms of protein
was separated using 12% SDS-polyacrylamide gel electrophoresis
under reducing conditions, and then transferred to a nitrocellu-
lose membrane (Sigma Chemical Co.). The nitrocellulose mem-
Fig. 9. Photomicrographs of endothelin-1 (ET-1) immunoreactivity in gb-
meruli of renal-ablated rats (magnification —.-X500). A. Typical glomerular
immunostaining for ET-1 in an untreated renal-ablated rat. B. Typical
glomerular immunostaining for ET-1 in a renal-ablated rat receiving
L-arginine.
brane was blocked with TTBS solution containing 5% non-fat
powdered milk, and incubated for one hour with monoclonal
PCNA antibody (Novocastra Laboratories Ltd., Newcastle-Upon-
Tyne, UK). Following a one hour incubation with a peroxidase
anti-mouse secondary antibody (Amersham Inc., Buckingham-
shire, UK), the Western blot was developed with an ECL Western
blotting analysis system (Amersham) using X-OMAT autoradiog-
raphy film (Eastman Kodak, Rochester, NY, USA). Autoradio-
grams were quantitated by scanning densitometry.
Immunohistochemistiy
Following brietal anaesthesia (50 mg/kg), the kidneys were
removed and the capsule excised. Eight cubic mm blocks of renal
cortical tissue were immersed in OCT compound (Miles Inc.), and
snap frozen in liquid nitrogen. Cryostat sections (5 jim) were
mounted on polyl-L lysine coated slides. Immunoperoxidase
staining was performed by the ABC method. In brief, sections
were fixed in acetone (4°C) and air dried. The sections were
washed for five minutes in tap water and incubated at room
temperature overnight with: (1) polyclonal rabbit PCNA antisera
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(R&D Systems, Minneapolis, MN, USA), diluted 1:250 in anti-
body diluting buffer (Dimension Laboratories Ltd, Mississauga,
Ontario, Canada), or (2) polyclonal rabbit endothelin-1 (human)
antisera (Peptide Institute, Osaka, Japan), diluted 1:250 in anti-
body diluting buffer (Dimension Laboratories). The anti-endothe-
lin-1 antibody cross-reacts with endothelin-2 (60%) and endothe-
lin-3 (40%), but exhibits little cross-reactivity to big endothelin 1
(1%). After a phosphate buffered saline wash (Dimension Labo-
ratories), tissue sections were incubated at at room temperature
for 30 minutes with an antirabbit IgG bioatinylated antibody
(Vectastain Elite Kit, Vector Laboratories, Burlingame, CA,
USA), diluted 1:200 with PBS. Finally, sections were washed and
then incubated for 30 minutes with an avidin-biotin-peroxidase
complex (diluted 1:50 in PBS). Sites of peroxidase activity were
visualized by incubation in DAB solution (Zymed Laboratories,
CA, USA) for two minutes. Sections were counterstained with
Harris modified hematoxylin with acetic acid (Fisher Scientific
Ltd) for five seconds, washed with tap water and covered with a
glass coverslip. Negative control experiments were performed by
either: (1) replacing the primary antibody with antibody diluting
buffer or (2) replacing the primary antibody with nonimmune
rabbit antiserum (1:4000).
Quantitative assessment of immunohistochemical staining
for PCNA
PCNA-positive nuclei were enumerated in all glomerular pro-
files in the cryostat sections from three renal-ablated rats in each
group. The total number of nuclei and the number of PCNA-
positive staining nuclei per glomerulus was determined in a
minimum of 25 glomeruli per rat. Immunoperoxidase staining had
to be clearly confined to cell nuclei in order to be considered
positive, as illustrated in Figure 1.
Semiquantitative assessment of immunohistochemical staining
for endothelin-1
The immunostaining was scored by examining glomerular pro-
files in cryostat sections from renal-ablated rats in each group.
Each profile was assigned a score from 0 to 4, where 0 is no
staining, 1 minimal (25% of the glomerular tuft), 2 mild (50% of
the glomerular tuft), 3 moderate (75% of the glomerular tuft), 4
marked (100% of the glomerular tuft). A score was derived for
each animal:
Score = Fi(i)
where Fi is the percentage of glomeruli in the rat with a given
score i [26—281.
Analysis
The statistical significance of differences among values of
individual parameters was evaluated by Student's t-test. Signifi-
cance was assigned to differences differences between individual
group means when P < 0.05. Values are expressed as mean
standard error. Urine protein excretion values were non-normally
distributed, and therefore results are expressed as geometric
means and ranges.
Results
Animal model
Preoperatively, the mean value for body wt was 217 8 g, and
the mean value for awake systolic blood pressure was 138 12
mm Hg. Urinary protein excretion rates averaged 4 1 mg124 hr.
The mean value for GFR was 10.5 1.74 ml/kg/min. Rats were
then subjected to 5/6 renal ablation, and randomly assigned to two
groups. A first group received L-arginine (1%) in the drinking
water, while a second group was untreated. Two weeks after renal
ablation, values for body wt averaged 241 4 g in the L-arginine
treated rats, and 247 2 g in the untreated rats (P> 0.05). Awake
systolic blood pressure increased in both groups of renal-ablated
rats, compared to the baseline measurements (P < 0.05), but
mean values were similar in the two groups two weeks after renal
ablation (164 13 mm Hg in the L-arginine treated rats and 172
13 mm Hg in the untreated rats, P> 0.05).
Renal function
As expected, 99Tc-DTPA clearance studies showed that GFR
was reduced in the renal-ablated rats. GFR averaged 5.6 3.5
mi/kg/mm in the L-arginine treated rats, and 3.8 1.9 mi/kg/mm
in the untreated rats. Although the mean value for GFR was
numerically greater in the L-arginine treated rats, compared to
the untreated rats, the difference did not reach statistical signifi-
cance (P > 0.05). Along with the increase in systolic blood
pressure, urinary protein excretion rates increased in both groups
of renal-ablated rats, compared to the baseline measurements,
averaging 52 1 mg/24 hr in the L-arginine treated rats (range 19
to 145 mg/24 hr), and 49 4 mg/24 hr in the untreated rats (range
14 to 174 mg/24 hr; P = NS by Wilcoxon's rank test). Values for
the remnant kidney weights were also similar in both groups of
rats, averaging 1.81 0.08 g in the L-arginine treated rats, and
1.81 0.06 g in the untreated rats.
PCNA expression
PCNA protein expression was demonstrated in the glomeruli of
L-arginine treated rats and untreated rats by immunohistochem-
ical analysis, and the results are illustrated in Figure 1. Figure 1A
is representative of the typical appearance of glomeruli from rats
when the primary antibody is omitted from the protocol or
replaced with non-immune serum. In the absence of specific
primary antiserum there is no immunoperoxidase staining in the
glomerular capillary tuft (magnification —500x). Figure lB shows
immunostaining for PCNA in the glomerulus of a renal-ablated
rat. Three positive immunostaining nuclei are evident.
PCNA positive nuclei were present in the glomeruli of renal-
ablated rats from both groups. Sections were scored by two
observers in a blinded fashion, and the number of positive-
staining nuclei and the total number of nuclei were enumerated in
each glomerular profile. Twenty-five giomeruli were counted per
rat. Significantly fewer positive staining nuclei were seen in the
L-arginine supplemented group (mean 2.07 1.44 in the L-
arginine treated renal-ablated rats vs. 3.25 1.42 for the un-
treated renal-ablated rats, P = 0.05). There was no difference
between the groups with regard to total number of cells per
glomerulus at two weeks (50.52 7.19 for L-arginine group vs.
51.88 9.42 in in the untreated group, P> 0.05).
To further assess PCNA expression, protein expression was
assessed by Western blot analysis in glomeruli from L-arginine
143—
97—
50—
35—
30—
22—
1 2 3 4
Ingram et al: L-arginine in the remnant glomerulus 1861
Fig. 2. Westem blot analysis for proliferating cell nuclear antigen (PCNA)
protein in glomeruli from untreated renal-ablated rats (lanes 1 and 3) and
renal-ablated rats treated with L-arginine (lanes 2 and 4). The positions of
molecular weight markers (kDa) are indicated in the margin of the
Western blot. PCNA was detected as a single band with a molecular of
approximately 36 kD in protein extracts from the glomeruli of both groups
of rats. PCNA expression was reduced in the glomeruli of the rats that
received dietary supplementation with L-arginine.
Fig. 3. Densitometiy measures of the Western blot analysis of PCNA protein
expression in glomeruli from renal-ablated rats receiving L-arginine (L-aig)
and untreated renal-ablated rats (Control). Dietary supplementation with
L-arginine reduced PCNA expression by 64%. N = 2 in each group.
treated rats and untreated rats, two weeks after renal ablation.
PCNA protein was detected as a single band with a molecular of
approximately 36 kD in protein extracts from the glomeruli of
both groups of rats (lanes ito 4, Fig. 2). The Western blot analysis
showed that PCNA protein expression was increased in the
glomeruli of the untreated renal-ablated rats (lanes 1 and lane 3,
Fig. 2) compared to the L-arginine treated renal-ablated rats
(lanes 2 and 4, Fig. 2). Scanning densitometry of the PCNA
Western blot revealed that L-arginine treatment reduced PCNA
expression by 64% (Fig. 3). The kidneys of three rats were pooled
for isolation of glomeruli and extraction of glomerular protein;
therefore, each lane represents a mean value for PCNA expres-
sion in the glomeruli of three renal-ablated rats.
Semiquantitative RT-PCR
The effect of L-arginine treatment on steady state mRNA levels
for endothelin-1 in the glomeruli of renal-ablated rats was deter-
Fig. 4. The RT-PCR products for glomerular endothelin-1 (ET-1) (A) and
3-actin (B) were visualized by UV transillumination of agarose gels contain-
ing ethidium bromide. The first lane in each of the panels shows the size
standards. A. The PCR product generated with the ET-1 primer pairs was
a single band between 500 and 600 base pairs. The predicted length was
543 base pairs. B. The PCR product generated with the 13-actin primer
pairs was a single band between 200 and 300 base pairs in size. The
predicted length was 240 base pairs.
Fig. 5. Coamplification RT-PCR analysis of mRNA levels for f3-actin. The
first lane is the size ladder. As expected RT-PCR yielded a single hand
between 200 and 300 base pairs (predicted size 240 base pairs). Lane one
shows the PCR product after 26 cycles of PCR; lane two shows 28 cycles;
lane three, 30 cycles; lane four, 32 cycles; lane five, 34 cycles. Standard
PCR amplification was performed for 30 cycles.
mined by co-amplification RT-PCR. A representative photograph
of the RT-PCR amplification products in a UV-transilluminated
agarose gel is illustrated in Figure 4. Figure 4A shows the PCR
product generated with the endothelin-1 primer pairs was a single
band between 500 and 600 bp. The predicted length was 543 bp.
Figure 4B shows the PCR product generated with the -actin
primer pairs was a single band between 200 and 300 bp in size.
The predicted length was 240 bp. Figure 5 shows that the p-actin
PCR product increases when the number of PCR cycles is
increased from 26 to 34.
Southern blot analysis of the RT-PCR products with specific
oligonucleotide probes is shown in Figure 6. Two weeks after
renal ablation, the ratio of the densitometry measures of the
RT-PCR products for endothelin-i to /3-actin was threefold
higher in untreated renal-ablated rats compared to L-arginine
treated renal-ablated rats (0.54 0.18 vs. 0.16 0.11, P < 0.05;
Fig. 7). mRNA levels were assessed in twelve rats from each group
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Fig. 6. Autoradiograph of the RT-PCR products for endothelin-1 (ET-])
and p-actin in glomeruli from L-arginine treated renal-ablated rats (lanes 1 to
3) and untreated renal-ablated rats (lanes 4 to 6).
Fig. 7. Ratio of the densitomety measures of mRNA levels for endothelin-1
(ET-1) and p-actin by RT-PCR in L-arginine treated renal-ablated rats
(L-arg) and untreated renal-ablated rats (Control). The ratio of ET-1 and
f3-actin was threefold greater in the untreated renal-ablated rats compared
to the L-arginine treated renal-ablated rats (N = 3 in each group). *p <
0.05 vs. control.
Fig. 8. One microgram of glomendar RNA (lanes 1 and 4) and one
microgram of cortical RNA (lanes 2 and 5) from two separate rats were
subjected to RT and then PCR with the primers for ET-1 and p-actin. Lane
3 shows the size ladder. ET-1 mRNA levels relative to -actin mRNA
levels were much less in cortical RNA samples than in glomerular RNA
samples with our amplification protocol.
for this analysis of steady state mRNA levels. Each lane repre-
sents a mean value for the mRNA level in the glomeruli of four
rats because the kidneys of four rats were pooled for isolation of
glomeruli and extraction of total RNA. Therefore, each lane in
Figure 6 represents a mean value for four renal-ablated rats.
To ensure that tubular contamination did not affect the assess-
ment of glomerular ET-1 mRNA levels by RT-PCR results,
co-amplification RT-PCR for ET-1 and f3-actin was performed
with RNA from renal cortex and isolated glomeruli of two normal
rats, and the results are illustrated in Figure 8. ET-1 mRNA levels
relative to 13-actin mRNA levels were much less in cortical RNA
samples than in glomerular RNA samples with our amplification
protocol.
Endothelin-1 immunohistochemistiy
To relate the change in mRNA levels for endothelin-1 to
differences in protein expression, ersdothelin-1 protein expression
was assessed in the glomeruli of L-arginine treated rats and
untreated rats by immunohistochemical analysis. The results are
illustrated in Figure 9. No immunoperoxidase staining was ob-
served in the glomerular capillary tuft of glomeruli from the
renal-ablated rats when the primary antibody was omitted from
Fig. 10. Glomerular endothelin-] (ET-]) immunostaining score in renal-
ablated rats receiving L-arginine (L-arg) and untreated renal-ablated rats
(Control). There was a significant decrease in ET-1 immunostaining in the
glomeruli of the rats receiving L-arginine. Values are mean I SD. j0
0.05 vs. Control (N = 6 in each group).
the protocol or replaced with non-immune serum (not shown).
Figure 9A shows glomerular immunostaining for endothelin-1 in
a glomerulus from an L-arginine treated rat, while Figure 9B
shows the typical glomerular immunostaining for endothelin-1 in
a glomerulus from the untreated rats.
Endothelin-1 immunostainirig was evident in the glomeruli of
rats from each of the experimental groups. Semiquantitative
scoring of glomerular immunostaining for endothelin-1 in the
L-arginine treated renal-ablated rats yielded a mean value of 0.9
0.6, while the mean score for endothelin-1 immunostaining in
the untreated renal-ablated rats was 2.1 0.3, so that glomerular
immunostaining for endothelin-1 was reduced by 50% in the
L-arginine treated rats (P < 0.05; Fig. 10).
Discussion
The remnant nephron exhibits hyperfiltration t, 5J and mi-
cropuncture studies have revealed prompt increases in glomerular
1862 Ingram et al: L-arginine in the remnant glomendus
SM S
- a a S a
D
en
si
to
m
et
ry
 ra
tio
, 
ET
- 1
/8
-a
ct
in
 
00
0 
P2
29
00
 
0 
a
 
01
 
01
 
4 
Im
m
un
os
ta
in
in
g 
sc
o
re
 fo
r e
n
do
th
el
in
-1
 
P 
P 
P 
0 
(P
 
0 
01
 
0 
01
 
0 
Ingram et al: L-arginine in the remnant glomendus 1863
capillary plasma flow rate and glonierular capillary hydrostatic
pressure [3]. Changes in glomerular hemodynamic function pre-
cede the development of glomeruloscierosis, and maneuvers that
normalize glomerular capillary hypertension limit glomerular
injury [8]. Mesangial cells in the remnant glomerulus undergo a
phenotypic change and begin to express smooth muscle alpha
actin [7], and an early phase of mesangial cellular proliferation
precedes the development of glomerulosclerosis [8]. In a recent
report, Klahr and co-workers studied the effect of dietary supple-
mentation with L-arginine on the development of glomeruloscle-
rosis in subtotally nephrectomized rats [9]. They found that
L-arginine treated rats developed significantly less glomerular
injury than untreated rats, although the mechanisms responsible
for this effect were not fully elucidated [9]. Accordingly, the first
goal of the present study was to determine if dietary supplemen-
tation with L-arginine limited the early phase of cell proliferation
in the glomeruli of 5/6 renal ablated rats.
We found that dietary supplementation with L-arginine re-
duced proliferating cell nuclear antigen (PCNA) expression in the
glomeruli of renal-ablated rats. PCNA is expressed in cells during
late GuS phase of the cell cycle so that the decline in PCNA
expression indicated that fewer cells were progressing through the
cell cycle [7]. Although double immunostaining studies were not
performed in the present study, Floege and coworkers have shown
that the predominant proliferating cell in the remnant glomerulus
is the mesangial cell [7]. Taken together with the reports of Reyes
and coworkers showing that dietary L-arginine attenuates glomer-
ular injury in the remnant kidney, our results suggest that one of
the mechanisms responsible for this beneficial effect may be an
early reduction in glomerular cell proliferation.
Dietary supplementation with L-arginine increases production
of nitric oxide (NO) by endothelial cells in vivo [26]. Although
Reyes and coworkers were unable to detect any rise in plasma
L-arginine levels in renal-ablated rats receiving L-arginine in their
drinking water [9], Ashab recently showed that the urinary
excretion of nitrite and nitrate rises renal-ablated rats receiving
L-arginine [141. NO is formed from the terminal guanidino
nitrogen of L-arginine by the action of nitric oxide synthases
(NOSs) [10, 27], and mRNA for both constitutive and inducible
nitric oxide synthases (NOS) is present glomerular endothelial
and mesangial cells [11, 12, 28, 29] so that NO can be synthesized
by these cells [11, 28, 30], as well as by whole glomeruli [12]. NO
inhibits mesangial cell contraction and proliferation in vitro [28,
31], and taken together, it is possible that dietary-induced in-
creases in glomerular NO production might be responsible for our
observation that PCNA expression was reduced in the glomeruli
of renal-ablated receiving dietary supplementation with L-argi-
nine. Further studies will be necessary to test confirm this
hypothesis.
ET-1 is produced by both glomerular endothelial cells and
mesangial cells [32—37], and in vitro, ET -1 increases Na/H
exchange, induces c-fos expression, and stimulates proliferation of
mesangial cells [17, 18, 38, 39]. Thus, ET-1 could play a role in
mediating the early phase of cellular proliferation in the remnant
glomerulus, and an attractive hypothesis is that dietary supple-
mentation with L-arginine might limit glomerular synthesis of
ET-1. Accordingly, the second goal of the present study was to
determine if dietary supplementation with L-arginine reduced
expression of ET-1 in the remnant glomerulus.
We found that dietary supplementation with L-arginine was
associated with a decline in mRNA levels for ET-1 in remnant
glomeruli, and the decline in mRNA levels was accompanied by a
significant decrease in glomerular ET-1 immunostaining, although
we did not establish that these effects were responsible for the
decrease in PCNA expression. ET-1 also increases mRNA levels
for collagen types I, III and IV in mesangial cells [40], and an
increase in ET-1 activity in the remnant glomerulus could to the
development of glomerulosclerosis. Since dietary L-arginine at-
tenuates glomerular injury in the remnant kidney [9, 41], our
results suggest that one of the mechanisms responsible for the
benefit of this maneuver may be a decrease in glomerular ET-1
expression, although other cytokines [7, 42—45] and physical
forces [3, 4] may affect cell proliferation and matrix production in
the remnant glomerulus, and may be altered by dietary supple-
mentation with L-arginine [46, 47].
A number of studies support a role for ET-1 in the pathophys-
iology of glomerular injury in the remnant kidney. Benigni and
co-workers initially investigated urinary ET-1 excretion and
thrombin-induced ET-1 production by renal cortical tissue and
isolated glomeruli from renal-ablated rats [19]. Urinary excretion
increased 45 days after renal ablation, and there was a significant
increase in thrombin-induced ET-1 production in the renal cortex
and glomeruli of rats 45 days after renal ablation. The same group
subsequently demonstrated that renal cortical mRNA levels for
ET-1 were increased significantly in remnant kidneys 30 days after
renal ablation, although glomerular mRNA levels were not as-
sessed [20]. Increases in ET-i expression in the remnant glomer-
ulus may be secondary to changes in glomerular capillary shear
stress [48], cytokines such as TGF-13 [49], or platelet-derived
thrombin [19]. Finally, the hypothesis that ET-1 plays an impor-
tant role in the development of glomerular injury is supported by
a preliminary report that an endothelin receptor antagonist limits
glomerular injury in the remnant kidney [50].
Dietary L-arginine increases the urinary excretion of NO
metabolites in renal-ablated rats [14], and it is possible that the
mechanism responsible for the effect of L-arginine on ET-1
expression is increased glomerular NO production. NO decreases
endothelin-1 (ET-1) release from cultured aortic endothelial cells
[15], and although the mechanism for this effect is unclear, sodium
nitroprusside (an NO donor) and cyclic GMP (the putative NO
second messenger) have also been shown to decrease ET-1
expression in endothelial cells [15, 32]. L-arginine analogs, which
limit the synthesis of NO, increase ET-1 secretion in rat and
human endothelial cells [15, 16], effects that are reversed by
L-arginine supplementation [51, 52].
The acute administration of L-arginine analog, which limit NO
synthesis, decrease renal plasma flow rates and glomerular filtra-
tion rates in rats [46, 47], and amplify the renal vasoconstrictor
response to angiotensin II [53]. Chronic administration of L-
arginine analogs raises glomerular capillary pressure and results
in glomerular injury in intact rats [54]. Micropuncture studies of
renal-ablated rats receiving L-arginine have shown that significant
decreases in mean values for efferent arteriolar resistance and
glomerular capillary hydrostatic pressure are not apparent until
several weeks after renal ablation [41], suggesting that the early
changes in PCNA and endothelin-i expression that we observed
were not due to decreases in glomerular capillary pressure.
In summary, we have shown that dietary supplementation with
L-arginine limits the early phase of cell proliferation in the
remnant glomerulus. An L-arginine induced decrease in PCNA
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expression in the remnant glomerulus is associated with a decline
in mRNA levels and protein expression for endothelin-1. These
observations suggest that early reductions in cell proliferation and
endothelin-1 expression may be responsible, in part, for the
attenuation of glomeruloscierosis in renal-ablated rats receiving
L-arginine.
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